|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02181 MABPHARM-B
Nominal 
0.410 -0.045 (-9.890%) Profitability Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| ROAA (%) | -12.475% | -21.445% | -23.200% | -28.284% | -14.427% |
| ROAE (%) | -87.041% | -69.094% | -42.041% | -39.333% | -19.081% |
| Return on Capital Employed (%) | -18.172% | -29.126% | -28.914% | -43.878% | -19.224% |
Margin Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Gross Profit Margin (%) | 84.961% | 86.321% | 72.504% | 79.758% | N/A |
| EBITDA Margin (%) | -21.910% | -159.743% | -272.656% | -298.518% | N/A |
| Pre-tax Profit Margin (%) | -49.548% | -240.195% | -377.015% | -351.999% | N/A |
| Net Profit Margin (%) | -49.548% | -240.195% | -377.015% | -351.999% | N/A |
Liquidity Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Current Ratio (X) | 1.172 X | 1.082 X | 1.068 X | 1.054 X | 2.809 X |
| Quick Ratio (X) | 0.816 X | 0.760 X | 0.532 X | 0.828 X | 2.644 X |
Leverage Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Total Liabilities / Total Assets(%) | 91.249% | 80.187% | 56.301% | 33.106% | 24.208% |
| Total Debt / Total Assets (%) | 28.841% | 25.128% | 13.769% | 5.077% | 3.469% |
| Net Debt / Total Assets (%) | 20.050% | 8.380% | 10.111% | -3.986% | -38.219% |
| Total Debt / Shareholders' Funds (%) | 329.561% | 126.830% | 31.510% | 7.590% | 4.577% |
| Long Term Debt / Shareholders' Funds (%) | 220.198% | 65.745% | 28.195% | 6.048% | 3.609% |
| Net Debt / Shareholders' Funds (%) | 229.100% | 42.295% | 23.138% | -5.958% | -50.426% |
| Net Cash / (Debt) ($) | (203.748M) | (86.728M) | (92.769M) | 35.866M | 444.498M |
| Net Cash / (Debt) per share ($) | (0.049) | (0.021) | (0.022) | 0.009 | 0.108 |
| Total Debt / Capital Employed (%) | 41.627% | 36.182% | 17.327% | 6.872% | 4.201% |
| Interest Coverage Ratio (X) | N/A | N/A | N/A | N/A | N/A |
Efficiency Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Inventory Turnover (Day) | 1001.208 Day | 3104.689 Day | 1828.062 Day | 942.447 Day | -- |
| Receivables Turnover (Day) | 80.532 Day | 60.627 Day | 33.698 Day | 3.492 Day | N/A |
| Payables Turnover (Day) | 15.351 Day | 55.692 Day | 96.103 Day | 38.151 Day | N/A |
| Remarks: | Real time quote last updated: 30/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -127,947,000 |
| %Change | -38.885% |
| EPS / (LPS) | RMB -0.030 |
| NBV Per Share (¥) | RMB 0.022 |